It seems that SGLT2 inhibitors demonstrated a protective effect in large vessels, whereas the effect was opposite in small vessels because of pre-existing lesions in DM2 associated with phenomena that promote stasis such as reduced blood pressure and hemoconcentration. Here, SLC5A2 is linked to myotonic dystrophy type 2.